US 8222203
Macrocyclic oximyl hepatitis C serine protease inhibitors
granted A61KA61K38/00A61P
Quick answer
US patent 8222203 (Macrocyclic oximyl hepatitis C serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Jul 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Tue Jul 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K38/00, A61P, A61P1/16, A61P31/14